Heather Warren
Psychiatric/Mental Health · Tallahassee, FLNPI 1992202659
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,571 of the $172,460 with a category attached, or 69.9%. 20 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 52.0% of the total. Reporting peaked in 2023 at $62,937 and has fallen 82.8% since, to $10,839 in 2025. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 469 payments — averaging $367.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$90K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$30K
- Teva Pharmaceuticals USA, Inc.$28K
- AbbVie$23K
- Otsuka America Pharmaceutical, Inc.$913
- Takeda Pharmaceuticals U.S.A., Inc.$412
- plus $1K from 14 others
What the payments were for
- Consulting fees$18,03810%
- Speaking & faculty fees$120,57170%
- Travel & lodging$22,76613%
- Food & beverage$11,0396%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 135 | $89,617 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $29,667 |
| Teva Pharmaceuticals USA, Inc. | 72 | $27,688 |
| AbbVie | 88 | $23,038 |
| Otsuka America Pharmaceutical, Inc. | 28 | $913 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $412 |
| Alkermes, Inc. | 8 | $254 |
| Sunovion Pharmaceuticals Inc. | 12 | $209 |
| Eisai Inc. | 6 | $196 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Merck | 4 | $68 |
| Jazz Pharmaceuticals Inc. | 3 | $66 |
| Johnson & Johnson(2 entities) | 3 | $47 |
| Almatica Pharma LLC | 3 | $47 |
| Indivior Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Bausch Health US, LLC | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$87,323
- CAPLYTA$28,546
- UZEDY$26,100
- VRAYLAR$21,689
- REXULTI$339
- AUSTEDO$118
- ABILIFY MAINTENA$117
- ABILIFY ASIMTUFII$117
- Dayvigo$109
How this compares
$172,460 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatric/mental health in Tallahassee
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
- Carolann BrooksCelebration$57K
- Linda SkalskyGainesville$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.